Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
| Market Cap | 10.67M | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
| Income | -2.88M | Forward P/E | - | EPS next Y | - | 50D Avg Chg | - |
| Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | -26.00% |
| Dividend | N/A | Price/Book | 0.09 | EPS next 5Y | - | 52W High Chg | -49.00% |
| Recommedations | - | Quick Ratio | 0.39 | Shares Outstanding | 169.13M | 52W Low Chg | - |
| Insider Own | 17.06% | ROA | -1.07% | Shares Float | 138.75M | Beta | 0.10 |
| Inst Own | - | ROE | -6.28% | Shares Shorted/Prior | -/- | Price | 0.04 |
| Gross Margin | - | Profit Margin | - | Avg. Volume | - | Target Price | - |
| Oper. Margin | - | Earnings Date | Dec 11 | Volume | 1,165 | Change | 0.00% |
About QUEST PHARMATECH INC
Quest PharmaTech Inc., a pharmaceutical company, engages in the development of novel therapeutics for the treatment of targeted cancer. The company's lead product candidate is Mab AR 9.6 against truncated O-glycan on MUC16, for the potential cancer targets include pancreatic, colon, leukemia, ovarian, and breast cancer. It is also involved in the development of Oregovomab, which is in Phase III clinical trial for the treatment of ovarian cancer. The company is headquartered in Edmonton, Canada.
QUEST PHARMATECH INC News